Skip to main content
NewslettersWatchlist

Elevation Oncology Inc(ELEV-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low3.50
Day High3.67
Open:3.59
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
Up 825% So Far in 2024, Can This Penny Stock Go Any Higher?
GlobeNewswire
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
PR Newswire
Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
PR Newswire
Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021
PR Newswire
Elevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business Achievements
PR Newswire
Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer
PR Newswire
Elevation Oncology Announces Pricing of $50 Million Public Offering
PR Newswire
Elevation Oncology Announces Launch of Proposed Public Offering
PR Newswire
Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023
MarketBeat
Steve Cohen's Point72 Disclosed 8.7% Stake In Elevation Oncology
PR Newswire
Elevation Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Business Achievements
PR Newswire
Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023
PR Newswire
Elevation Oncology Presents EO-3021 Preclinical Proof-of-Concept Data and Highlights a Clinical Case Study in Claudin 18.2-Expressing Cancers at AACR 2023
PR Newswire
Elevation Oncology to Present at the American Association of Cancer Research (AACR) Annual Meeting 2023
PR Newswire
Elevation Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
MarketBeat
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
PR Newswire
Elevation Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
PR Newswire
Elevation Oncology Announces Pipeline Prioritization, Realignment of Resources to Advance EO-3021 and CEO Transition
PR Newswire
Elevation Oncology to Participate at the JMP Securities Hematology and Oncology Summit
PR Newswire
Elevation Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
PR Newswire
Elevation Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
PR Newswire
Elevation Oncology to Participate at the Wedbush PacGrow Healthcare Conference
PR Newswire
Elevation Oncology Secures $50 Million Loan Facility with K2 HealthVentures
PR Newswire
Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group
PR Newswire
Elevation Oncology Announces the Promotion of Valerie Malyvanh Jansen, M.D., Ph.D., to Chief Medical Officer

Profile

Elevation Oncology Inc. is a clinical stage biopharmaceutical company. It focused on the development of precision medicines for patients with genomically defined cancers. Elevation Oncology Inc. is based in NEW YORK.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright ยฉ 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright ยฉ 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.